US 11,987,794 B2
Products and compositions
Judith Hauptmann, Berlin (DE); Dmitry Samarsky, Berlin (DE); Adrien Weingärtner, Berlin (DE); Lucas Bethge, Berlin (DE); Christian Frauendorf, Berlin (DE); and Alison Gallafent, Berlin (DE)
Assigned to Silence Therapeutics GMBH, Berlin (DE)
Filed by Silence Therapeutics GmbH, Berlin (DE)
Filed on Mar. 7, 2022, as Appl. No. 17/688,789.
Application 17/688,789 is a continuation of application No. 16/500,770, granted, now 11,414,660, previously published as PCT/EP2018/058762, filed on Apr. 5, 2018.
Claims priority of application No. 17165058 (EP), filed on Apr. 5, 2017; application No. 17201353 (EP), filed on Nov. 13, 2017; and application No. 17201447 (EP), filed on Nov. 13, 2017.
Prior Publication US 2022/0290143 A1, Sep. 15, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/11 (2006.01); C12N 15/113 (2010.01)
CPC C12N 15/113 (2013.01) [C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/317 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/344 (2013.01); C12N 2320/51 (2013.01)] 22 Claims
 
1. A nucleic acid for inhibiting expression of a target gene in a cell, comprising at least one duplex region that comprises at least a portion of a first strand and at least a portion of a second strand that is at least partially complementary to the first strand, wherein said first strand is 17-35 nucleotides in length and/or said second strand is 17-35 nucleotides in length, wherein said first strand is at least partially complementary to at least a portion of RNA transcribed from said target gene to be inhibited, wherein the terminal nucleotide at the 3′ end of at least one of the first strand and the second strand is an inverted nucleotide and is attached to the adjacent nucleotide via the 3′ carbon of the terminal nucleotide and the 3′ carbon of the adjacent nucleotide and/or the terminal nucleotide at the 5′ end of at least one of the first strand and the second strand is an inverted nucleotide and is attached to the adjacent nucleotide via the 5′ carbon of the terminal nucleotide and the 5′ carbon of the adjacent nucleotide, and wherein the inverted nucleotide is an inverted ribonucleotide comprising a sugar moiety that does not have a chemical modification.